177lu-nym032
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2024 (NCT06383052)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
Chemistry & pharmacology
- Payload
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06389695 | Phase 1 | May 31, 2024 | Norroy Bioscience Co., LTD |
| NCT06383052 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2024 | Jiangnan University, Norroy Bioscience Co., LTD |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Norroy Bioscience Co., LTD | For profit | 2 | 2 | 2 | 2024 |
| Jiangnan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1